SecBot SecBot
Biotech Drug Report Generated Nov 10, 2026

ABCL635

ABCL·AbCellera Biologics Inc.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Phase 2
Time to market
Phase 3 is planned to begin in 2027. Assuming a multi-year Phase 3 program followed by FDA review, potential approval would likely be 2029-2030 at the earliest, barring accelerated development.
Why 4/10
The Phase 2 topline readout (the most recent binary catalyst) occurred on August 10, 2026, and the next hard dated catalyst is the planned Phase 3 initiation in 2027, which is not a binary regulatory or pivotal readout. With no PDUFA or pivotal topline readout scheduled within the next ~12 months, the impact score is capped at 4.
Actionable Insight NEUTRAL

The next major catalyst for ABCL635 is the planned Phase 3 start in 2027, which the company confirmed on its Q3 2026 earnings call. Positive Phase 2 data (83% vs 33% placebo reduction in hot flash frequency) has already been reported, so the stock's next binary event is likely years away. Watch for FDA feedback on Phase 3 trial design and any partnership/licensing deals that could validate the asset's value.

Price Chart

Loading chart...

Executive Summary

ABCL635 is AbCellera Biologics' lead wholly-owned pipeline asset, a monoclonal antibody targeting NK3R for non-hormonal treatment of moderate-to-severe hot flashes (vasomotor symptoms) due to menopause. In August 2026, the company reported positive Phase 2 topline data showing an 83% reduction in hot flash frequency versus 33% on placebo after a single dose, which the company calls best-in-class. The stock surged ~100% on the news, and the company raised $200M in an oversubscribed offering to fund development. AbCellera plans to advance ABCL635 into Phase 3 in 2027. The drug faces established oral competitors (Astellas' Veozah and Bayer's Lynkuet) but differentiates with monthly injectable dosing. Analyst consensus is strongly bullish with a mean price target of $17.17, representing ~37% upside from the current $12.50.

How It Works

ABCL635 is a monoclonal antibody that blocks the neurokinin 3 receptor (NK3R), a protein involved in the brain's temperature regulation center. By blocking NK3R, the drug aims to reduce the frequency and severity of hot flashes (vasomotor symptoms) in menopausal women without using hormones. It is designed as a long-acting injectable, potentially requiring only monthly dosing.

Trial Status

Phase 2 portion of a Phase 1/2 trial (NCT07118891) has completed enrollment (136 patients) and reported positive topline results on August 10, 2026. The trial is active but not recruiting, with estimated primary completion in February 2027. Phase 3 is planned to start in 2027.

The Two-Sided Case

▲ Bull Case6
Phase 2 data showed an 83% reduction in moderate-to-severe hot flash frequency versus 33% on placebo after a single dose, which the company describes as best-in-class.
ABCL635 offers a differentiated monthly injectable dosing regimen versus daily oral pills (Veozah, Lynkuet), potentially improving compliance and convenience.
The company raised $200M in an oversubscribed offering after Phase 2 data, providing a strong cash runway to fund Phase 3 development.
Analyst consensus is strongly bullish: 16 Buy/Strong Buy ratings, 2 Hold, 0 Sell, with a mean price target of $17.17 (37% upside from $12.50).
Insiders purchased shares after Phase 2 data: director Michael Hayden bought ~$1M and CFO Andrew Booth bought ~$384K, signaling confidence.
The addressable U.S. market for moderate-to-severe vasomotor symptoms is estimated at $6B+, and ABCL635 is AbCellera's lead wholly-owned pipeline asset.
▼ Bear Case5
ABCL635 faces entrenched oral competitors already on the market: Astellas' Veozah (fezolinetant) and Bayer's Lynkuet (elinzanetant), both daily pills approved for the same indication.
As an injectable antibody, ABCL635 may face payer and patient adoption hurdles versus convenient daily oral pills, even with monthly dosing.
The company is still pre-revenue on its own pipeline and posted a Q3 2026 operating loss of $40.8M, requiring continued capital raises beyond the $200M oversubscribed offering.
Several large institutional holders trimmed or exited positions in Q2 2026 (Goldman Sachs near-exit, Millennium Management trim), suggesting some skepticism about valuation.
Phase 3 trials are expensive and carry execution risk; the drug is still years from potential FDA filing and commercialization.

Upcoming Catalysts

  • Phase 3 trial initiation in 2027 (no specific date announced)
  • Potential data presentations at medical conferences (TMS 2026 Annual Meeting presentation already scheduled for October 2026)
  • FDA feedback on Phase 3 trial design
  • Any potential partnership or licensing deal for ABCL635

Source Filing

The SecBot filing or press-release report that triggered this drug report:

AbCellera Biologics Inc. 8-K ABCL ·Originating report

Sources · 7

Hover a chip for the title
1 morningstar.com2 247wallst.com3 businesswire.com4 seekingalpha.com5 seekingalpha.com6 msn.com7 seekingalpha.com